Molecular tumour boards — current and future considerations for precision oncology

Nature Reviews Clinical Oncology, Published online: 16 October 2023; doi:10.1038/s41571-023-00824-4According to the precision oncology paradigm, cancer therapies are increasingly being matched to specific sensitizing alterations using a biomarker-directed approach. However, the criteria for determining the actionability of molecular alterations and selecting matched treatments evolve over time. Molecular tumour boards (MTBs) have emerged as means to capitalize on the collective knowledge of various experts to interpret molecular-profiling data and to eliminate subjectivity in treatment selection. This Review describes the components, processes and increasingly important role of MTBs in optimizing the implementation of precision oncology in both clinical trials and clinical practice, as well as current and future considerations for ensuring the sustainability of MTBs and expanding their outreach to underserved populations.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research